Is it time to rethink how neuropsychological tests are used to diagnose mild forms of HIV-associated neurocognitive disorders? Impact of false-positive rates on prevalence and power.
about
Evolving clinical phenotypes in HIV-associated neurocognitive disordersThe Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical ReviewInterpersonal psychotherapy for depression and posttraumatic stress disorder among HIV-positive women in Kisumu, Kenya: study protocol for a randomized controlled trialNeurocognitive function in HIV-infected patients: comparison of two methods to define impairmentMinimal cognitive impairment in UK HIV-positive men who have sex with men: effect of case definitions and comparison with the general population and HIV-negative menCerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection.Interactions between ageing and NeuroAIDS.Association between brain volumes and HAND in cART-naïve HIV+ individuals from Thailand.Gait Patterns in Patients with Hereditary Spastic Paraparesis.Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial.A comparison of the sensitivity, stability, and reliability of three diagnostic schemes for HIV-associated neurocognitive disorders.Neurologic Complications in Treated HIV-1 Infection.A Screening Strategy for HIV-Associated Neurocognitive Disorders That Accurately Identifies Patients Requiring Neurological Review.Predictors and Impact of Self-Reported Suboptimal Effort on Estimates of Prevalence of HIV-Associated Neurocognitive Disorders.Normative comparisons for large neuropsychological test batteries: User-friendly and sensitive solutions to minimize familywise false positives.Dementia in motor neuron disease: Reviewing the role of MRI in diagnosis.Assessment of neurological soft signs in pediatric patients with HIV infection
P2860
Q26859192-58CCF069-1C21-4E01-82E0-E33421014B3FQ28066725-54153926-D6F8-4DA6-AE88-B9423DF8B8ADQ28601428-1AA5B858-949D-4C47-A092-99B319B5ED45Q33982015-FA966251-F34E-4F77-8B8F-753A81C24136Q34243885-C35F1D9F-8E87-4C8A-8413-95DCA48F385FQ34776835-7DA1ACF7-419B-407F-95A6-D4B2301C5AE2Q34977613-A50AF176-C124-4A62-9DCE-F60515442D13Q35220349-0F21B788-5C0F-48DE-9AFF-9E1D7A91CF93Q36161484-D502A5A4-97D3-4CE0-BCE4-4E6D4A4E1172Q37055030-4D56943A-07BF-4719-9994-59BC09FCAD34Q38767650-863B77F9-47E8-41ED-BE92-28F301B31C00Q38832560-7F214F68-61A5-4BD4-8943-35972A835AD2Q38871573-62FFBB2E-3ECA-4199-8D0C-492416A935A3Q38886999-9BDF25A7-BA7F-4B82-A81B-C9933A8823E8Q39775336-02BFA1F5-59B0-419E-B331-B2577BAE4412Q47098663-097B4778-CD82-4171-9EDE-E9210A61E59DQ57146586-092FFA48-FFA8-4A2D-B65E-8CBD6C652183
P2860
Is it time to rethink how neuropsychological tests are used to diagnose mild forms of HIV-associated neurocognitive disorders? Impact of false-positive rates on prevalence and power.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Is it time to rethink how neur ...... rates on prevalence and power.
@ast
Is it time to rethink how neur ...... rates on prevalence and power.
@en
type
label
Is it time to rethink how neur ...... rates on prevalence and power.
@ast
Is it time to rethink how neur ...... rates on prevalence and power.
@en
prefLabel
Is it time to rethink how neur ...... rates on prevalence and power.
@ast
Is it time to rethink how neur ...... rates on prevalence and power.
@en
P2093
P2860
P356
P1433
P1476
Is it time to rethink how neur ...... rates on prevalence and power.
@en
P2093
Judith K Kwasa
Richard W Price
W John Boscardin
P2860
P304
P356
10.1159/000354629
P577
2013-10-23T00:00:00Z